On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter revenues of $4.21 billion, beating the ...
Neurology Sales Growth: 10% in Q3 2024. Endoscopy Sales Growth: 7% organically in Q3 2024. Boston Scientific Corp ...
23h
Good morning, Boston. Here are the five things you need to know in local business news to start your busy Thursday.
Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared ...
In a report released today, Matthew Taylor from Jefferies maintained a Buy rating on Boston Scientific (BSX – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback